AzTrials
AzTrials

Knee Pain ChronicNCT07800676

A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain

A study testing A+HA premium oral hyaluronic acid drink in people with Knee Pain Chronic, run by Taipei Medical University at 1 site in Taiwan.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

Evaluate the effect of A+HA premium oral hyaluronic acid drink on relieving knee pain. Read more about this study

Who is it for?
Ages 45 to 80 years
Conditions the study is for
Knee Pain Chronic
What is being tested?
A+HA premium oral hyaluronic acid drink
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteTaiwan
Study dates
1 Sep 2026to 28 Feb 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 45 to 80 years.
  • Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade <3.
  • A Visual Analogue Scale (VAS) pain score ≤3.
  • A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score >2 or a total WOMAC score >12.

Who cannot join

  • Pregnant or breastfeeding women.
  • Individuals with a history of knee joint trauma or surgery.
  • A body mass index (BMI) ≥ 40 kg/m².
  • Individuals with a psychiatric disorder.
  • Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
  • Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
Show all 10Show fewer
  • Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
  • Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
  • Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
  • Any other condition considered by the physician to make the individual unsuitable for participation in the trial.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Taiwan1 site
  • Taipei Medical University

    Taipei

    YiWen Chien, PhD, +886 2-27361661 #28363, ychien@tmu.edu.tw

Other trials in Taiwan

About this study

Evaluate the effect of A+HA premium oral hyaluronic acid drink on relieving knee pain.

Read the detailed description

Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.

Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.

Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.

Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.

Being tested
Placebo, A+HA premium oral hyaluronic acid drink
Keywords
Knee pain, Hyaluronic acid, Chondroitin, Glucosamine hydrochloride

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDietary supplement

    1 drink daily

  • A+HA premium oral hyaluronic acid drinkDietary supplement

    1 drink daily

Study groups in NCT07800676
Study groupRoleWhat they receive
PlaceboPlacebo comparatorPlacebo use contents without active ingredients
Receives: Dietary Supplement: Placebo
A+HA premium oral hyaluronic acid drinkExperimentalA+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
Receives: Dietary Supplement: A+HA premium oral hyaluronic acid drink

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Points change of pain evaluation scale

    Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain. Explain to the subjects that the pain intensity increases from left to right. Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark. Record the points that the subjects wrote.

    Measured: From the start to the end of treatment at 12 weeks

  2. Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points). The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points). The higher score meant worse knee joint function. Record the points that the subjects got.

    Measured: From the start to the end of treatment at 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Sep 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion31 Jan 2027 (estimated)
  4. Study completion28 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07800676
Sponsor's protocol ID
N202606002
Status last verified
Jun 2026
First submitted
12 Aug 2026
Last updated
2 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in